Harold:
I've worked extensively with this antibody, during quality control work at PharMingen. I've also worked a bit with a demyelinating model in SJL mice. However, I'm not quite certain of what they're trying to say here, so I've decided that I should read the entire paper before commenting (I saw the abstract posted in the BGEN thread, as you know).
So, I think that I need to hit a medical library before opening mouth and inserting foot.
:-)
I still stand on what I've said previously.... while I expect anti-CD40L to be a blockbuster agent, I believe that the *proposed* mechanism for 507 is superior for at least certain diseases. The relative lack of preclinical data for 507 could reflect the expression of the epitope only on human, gorilla and chimp cells (one can't do experiments short of clinicals in humans, which, according to the MEDI conference call, are going well). There are experiments in rats that indicate, to me, that a similar antibody may have been described there. Open question.
Thanks!
Rick |
